Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268615 | 0.84 | TSHR (0.33) | — | |
| SCHEMBL27598461 | 0.75 | ALDH1A1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL1267577 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL10510809 | 0.73 | TSHR (0.41) | — | |
| SCHEMBL31163977 | 0.73 | TSHR (0.39) | — | |
| SCHEMBL1267576 | 0.73 | CA2 (0.30) | CA2 | |
| SCHEMBL3772772 | 0.71 | — | — | |
| SCHEMBL11570348 | 0.70 | TSHR (0.40) | CA2 | |
| SCHEMBL13922207 | 0.70 | TSHR (0.40) | CA2 | |
| SCHEMBL6246216 | 0.70 | TSHR (0.40) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-7855302-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7692034-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-06 | — | — | US | disclosed |
| EP-2161250-A1 | Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| EP-1404642-B1 | Process for the preparatiom of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7504532-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20080312466-A1 | Synthesis and intermediates | OHRLEIN REINHOLD | 2008-12-18 | — | — | US | disclosed |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | BASF SE (DE) | 2008-05-29 | — | — | US | disclosed |
| US-7317123-B2 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2008-01-08 | — | — | US | disclosed |
| US-20070142662-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2007-06-21 | — | — | US | disclosed |
| US-7199261-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-04-03 | — | — | US | disclosed |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | BASF SE (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | HMGCR, SREBF1, LCAT | CA2 910/4885 |
| US-20080312466-A1 | Synthesis and intermediates | HMGCR, SREBF1, COASY | CA2 1130/4885 |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | HMGCR, DHCR7, CYP8B1 | CA2 2263/4885 |
| US-20070142662-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | HMGCR, DHCR7, HCAR3 | CA2 770/4885 |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | HMGCR, DHCR7, HCAR3 | CA2 770/4885 |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | HMGCR, DHCR7, CYP8B1 | CA2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.